EG20300A - Procede de preparation de concentre de facteur von willebrand humain de tres haute purete approprie a un usage therapeutic - Google Patents

Procede de preparation de concentre de facteur von willebrand humain de tres haute purete approprie a un usage therapeutic

Info

Publication number
EG20300A
EG20300A EG13192A EG13192A EG20300A EG 20300 A EG20300 A EG 20300A EG 13192 A EG13192 A EG 13192A EG 13192 A EG13192 A EG 13192A EG 20300 A EG20300 A EG 20300A
Authority
EG
Egypt
Prior art keywords
preparation
high purity
therapeutic use
von willebrand
willebrand factor
Prior art date
Application number
EG13192A
Other languages
English (en)
French (fr)
Inventor
Thierry Burnouf
Original Assignee
Centre Regional De Transfusion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Regional De Transfusion filed Critical Centre Regional De Transfusion
Application granted granted Critical
Publication of EG20300A publication Critical patent/EG20300A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EG13192A 1991-03-08 1992-03-07 Procede de preparation de concentre de facteur von willebrand humain de tres haute purete approprie a un usage therapeutic EG20300A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9102804A FR2673632A1 (fr) 1991-03-08 1991-03-08 Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.

Publications (1)

Publication Number Publication Date
EG20300A true EG20300A (fr) 1998-10-31

Family

ID=9410505

Family Applications (1)

Application Number Title Priority Date Filing Date
EG13192A EG20300A (fr) 1991-03-08 1992-03-07 Procede de preparation de concentre de facteur von willebrand humain de tres haute purete approprie a un usage therapeutic

Country Status (29)

Country Link
US (1) US5408039A (enExample)
EP (1) EP0503991B1 (enExample)
JP (1) JP3435668B2 (enExample)
AT (1) AT407115B (enExample)
AU (1) AU645172B2 (enExample)
BE (1) BE1004178A3 (enExample)
BR (1) BR9200770A (enExample)
CA (1) CA2062340C (enExample)
CZ (1) CZ283633B6 (enExample)
DE (2) DE69227055T2 (enExample)
DK (1) DK0503991T3 (enExample)
EE (1) EE03057B1 (enExample)
EG (1) EG20300A (enExample)
ES (1) ES2121830T3 (enExample)
FI (1) FI106721B (enExample)
FR (1) FR2673632A1 (enExample)
HU (1) HU215098B (enExample)
IL (1) IL101043A (enExample)
IT (1) IT1256692B (enExample)
LT (1) LT3175B (enExample)
NL (1) NL300394I1 (enExample)
NO (1) NO301278B1 (enExample)
NZ (1) NZ241701A (enExample)
PL (1) PL168353B1 (enExample)
RU (1) RU2088590C1 (enExample)
SA (1) SA92120446B1 (enExample)
SK (1) SK279533B6 (enExample)
UA (1) UA27732C2 (enExample)
ZA (1) ZA921430B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
DE19616540A1 (de) * 1995-11-10 1997-05-15 Immuno Ag Verwendung von von Willebrand-Faktor und pharmazeutische Zubereitung
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
US6068838A (en) * 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
AT404358B (de) 1997-02-04 1998-11-25 Immuno Ag Verfahren zur chromatographischen reinigung bzw. fraktionierung von von willebrand-faktor aus einem vwf-hältigen ausgangsmaterial
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) * 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
PT2193809E (pt) 1999-02-22 2015-08-24 Baxter Int Formulações de fator viii livres de albumina
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
RU2200028C2 (ru) * 2000-06-20 2003-03-10 Кировский НИИ гематологии и переливания крови Способ пломбировки пункционного канала после диагностической эндоскопической пункционной биопсии печени у больных гемофилией а
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
FR2874216B1 (fr) * 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu
DE102004044419B4 (de) 2004-09-14 2010-04-15 Biotest Ag Verfahren zur Aufreinigung eines von Willebrand Faktors mittels Hydroxylapatit-Durchlaufchromatographie
DE102004044429B4 (de) * 2004-09-14 2009-04-30 Biotest Ag Verfahren zur Herstellung einer Zusammensetzung enthaltend von Willebrand Faktor
ITLU20070007A1 (it) * 2007-05-07 2008-11-08 Kedrion Spa Processo cromatografico per l'ottenimento di un complesso fviii/vwf con differenti rapporti tra le due proteine da utilizzare nella terapia della emofilia a e nella malattia di von willebrand.
EP2486936A1 (en) 2007-06-13 2012-08-15 CSL Behring GmbH A composition comprising VWF and FVIII preparations for use in treating of bleeding disorders
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
EP2073015A1 (en) 2007-12-21 2009-06-24 CSL Behring GmbH Diagnostic in vitro method for assessing Von Willebrand Disease and bleeding risk associated with Von Willebrand Disease and acquired or congenital disorders of platelet function
US20100273206A1 (en) * 2007-12-21 2010-10-28 Manfred Rauh Diagnostic in vitro method for assessing von willebrand disease and increased bleeding risk associated with von willebrand disease and acquired or congenital disorders of platelet function
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
BRPI0921429B1 (pt) * 2008-11-07 2022-07-12 Takeda Pharmaceutical Company Limited Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
IT1396528B1 (it) 2009-01-19 2012-12-14 Kedrion Spa Nuovo processo di purificazione altamente selettivo di due proteine plasmatiche: von willebrand factor (vwf) e fibronectina (fn).
AU2010284977A1 (en) 2009-08-20 2012-03-29 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
AU2011343813B2 (en) 2010-12-15 2015-05-21 Takeda Pharmaceutical Company Limited Eluate collection using conductivity gradient
KR20140083035A (ko) 2011-10-18 2014-07-03 체에스엘 베링 게엠베하 인자 ｖｉｉｉ의 생체이용률을 증가시키기 위한 황산화 글리코사미노글리칸과 하이알루로니다제의 병용 사용
KR20140083036A (ko) 2011-10-18 2014-07-03 체에스엘 베링 게엠베하 인자 ｖｉｉｉ의 생체이용률을 향상시키기 위한 황산화 글리코사미노글리칸의 용도
PL2814502T3 (pl) 2012-02-15 2018-02-28 Csl Behring Gmbh Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
ES2693380T3 (es) 2013-11-08 2018-12-11 Csl Limited Nuevo método para concentrar el factor de von Willebrand o complejos de este
EP3164150B1 (en) 2014-07-02 2020-11-04 CSL Behring Lengnau AG Modified von willebrand factor
US10626164B2 (en) 2014-07-25 2020-04-21 Csl Limited Purification of VWF
FR3034669B1 (fr) 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
EP3362464B1 (en) * 2015-10-15 2021-04-28 Plasma Technologies LLC Methods for extracting proteins from blood plasma
RU2018128582A (ru) 2016-01-07 2020-02-11 Цсл Беринг Ленгнау Аг Мутированный укороченный фактор фон виллебранда
DK3400238T3 (da) 2016-01-07 2021-07-26 CSL Behring Lengnau AG Muteret von willebrand faktor
CN105622746A (zh) * 2016-02-04 2016-06-01 江西博雅生物制药股份有限公司 一种从冷沉淀提取凝血因子ⅷ的废料中提取人血管性血友病因子的制备工艺
CN105622747A (zh) * 2016-02-04 2016-06-01 江西博雅生物制药股份有限公司 一种vWF活性保护液
CN105541997A (zh) * 2016-02-04 2016-05-04 江西博雅生物制药股份有限公司 一种高纯度和高活性血管性血友病因子的制备工艺
EP3488858A1 (en) 2017-11-27 2019-05-29 Laboratoire Français du Fractionnement et des Biotechnologies A von willebrand factor composition for use in treating a pathology mediated by angiogenesis
CN114249812B (zh) * 2020-09-22 2023-09-15 四川远大蜀阳药业有限责任公司 一种降低vWF制品中IgM含量的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61166542A (ja) * 1985-01-18 1986-07-28 Hitachi Chem Co Ltd 感光性組成物
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
US5006642A (en) * 1987-06-29 1991-04-09 Rhone-Poulenc Rorer Pharmaceuticals Inc. Purification of von Willebrand Factor by affinity chromatography
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus

Also Published As

Publication number Publication date
IL101043A0 (en) 1992-11-15
JP3435668B2 (ja) 2003-08-11
US5408039A (en) 1995-04-18
HUT63176A (en) 1993-07-28
ITTO920189A0 (it) 1992-03-06
DE69227055T2 (de) 1999-04-22
CS56892A3 (en) 1992-09-16
AU645172B2 (en) 1994-01-06
UA27732C2 (uk) 2000-10-16
ZA921430B (en) 1992-11-25
FR2673632B1 (enExample) 1995-05-05
DE122009000034I1 (de) 2010-04-08
EE03057B1 (et) 1997-12-15
NO920867D0 (no) 1992-03-05
NL300394I1 (nl) 2009-09-01
SA92120446B1 (ar) 2004-05-04
EP0503991B1 (fr) 1998-09-23
AT407115B (de) 2000-12-27
PL168353B1 (pl) 1996-02-29
LT3175B (en) 1995-02-27
CA2062340C (fr) 2000-05-09
PL293738A1 (en) 1992-09-21
HU215098B (hu) 1998-09-28
AU1113192A (en) 1992-09-10
FR2673632A1 (fr) 1992-09-11
BE1004178A3 (fr) 1992-10-06
IL101043A (en) 1997-02-18
NO920867L (no) 1992-09-09
IT1256692B (it) 1995-12-12
RU2088590C1 (ru) 1997-08-27
DE122009000034I2 (de) 2011-06-16
NO301278B1 (no) 1997-10-06
HU9200767D0 (en) 1992-05-28
JPH0597696A (ja) 1993-04-20
ATA43692A (de) 2000-05-15
ITTO920189A1 (it) 1993-09-06
CZ283633B6 (cs) 1998-05-13
NZ241701A (en) 1994-10-26
FI920992L (fi) 1992-09-09
LTIP266A (en) 1994-07-15
DE69227055D1 (de) 1998-10-29
CA2062340A1 (fr) 1992-09-09
DK0503991T3 (da) 1999-06-14
FI106721B (fi) 2001-03-30
BR9200770A (pt) 1992-11-17
FI920992A0 (fi) 1992-03-06
EP0503991A1 (fr) 1992-09-16
SK279533B6 (sk) 1998-12-02
ES2121830T3 (es) 1998-12-16

Similar Documents

Publication Publication Date Title
EG20300A (fr) Procede de preparation de concentre de facteur von willebrand humain de tres haute purete approprie a un usage therapeutic
MA20739A1 (fr) Procede de preparation d'hydroxyalkylxanthines tertiaires
FI102182B1 (fi) Menetelmä ihmisen insuliinianalogien valmistamiseksi
EP0222385A3 (en) Sex hormones for the treatment of immunodeficiency diseases
DK473088D0 (da) Anvendelse af 2-amino-6-trifluormethoxybenzothiazol til fremstilling af et laegemiddel
DK473288D0 (da) Anvendelse af 2-amino-6-trifluormethoxybenzothiazol til fremstilling af et laegemiddel
LV10391A (lv) Alkilfosforskabes savienojumu izmantosana psoriazes tipa slimibu arstesanai
FI923662L (fi) Terapeutiska medel
DK484186A (da) Fremgangsmaade til fremstilling af et praeparat til behandling af psoriasis
ITPD910141A1 (it) Procedimento perfezionato per la realizzazione di calzature
GB8523878D0 (en) Therapeutic compounds
EP0648268A4 (en) THERAPEUTIC FRAGMENTS OF THE WILLEBRAND FACTOR.
GB8621738D0 (en) Reusable adjustable nappy
DK651588A (da) Anvendelse af en forbindelse til fremstilling af et farmaceutisk praeparat til behandling af fibromyalgia
FI91069B (fi) Menetelmä 5-C-hydroksimetyylialdoheksoosipohjaisten yhdisteiden valmistamiseksi
IT8667965A0 (it) Del prodotto guadagno banda per amsistema per il controllo automatico plificatori operazionali
FR2585267B1 (fr) Arroseur pulsatoire
FI940338L (fi) Menetelmä 13alfa-sinnamoyylibakkatiini III:n tai -10-desasetyylibakkatiini III:n valmistamiseksi
FI923744A7 (fi) Menetelmä ja välituotteita 6-fluoribentsisotiatsolien valmistamiseksi
FR2587330B1 (fr) Nouveau procede de preparation des undecatrienes
ITMI913375A0 (it) Procedimento per la produzione di neuraminidasi
ITMI913141A1 (it) Procedimento per la preparazione di carbonati alchilici
EP0272929A3 (en) Enkephalinase for therapeutic use
FR2589860B1 (fr) Nouveau procede de preparation des n-nitrosourees
GR861428B (en) Therapeutic compounds